報告摘要

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection. Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc. Report Scope This report quantifies the global Drugs for Herpes Labialis (Oral Herpes) market in terms of revenue (US$ million) and, where applicable, service volume (K MT), using 2024 as the base year and providing annual historical and forecast data for 2021–2032. It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K MT) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drugs for Herpes Labialis (Oral Herpes). Key Companies & Market Share Insights This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking. Drugs for Herpes Labialis (Oral Herpes) Market by Company GSK Novartis Teva Mylan Cadila Apotex Daewoong Pharmaceutical Livzon Luoxin Med shine Bayer (Campho Phenique) Blistex Kelun Hikma Haiwang Carmex Cipher Drugs for Herpes Labialis (Oral Herpes) Segment by Type Aciclovir Valacyclovir Famciclovir Docosanol Other Drugs for Herpes Labialis (Oral Herpes) Segment by Application External Use Oral Injection Drugs for Herpes Labialis (Oral Herpes) Segment by Region North America United States Canada Mexico Europe Germany France U.K. Italy Spain Russia Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Middle East & Africa Saudi Arabia Israel United Arab Emirates Turkey Iran Egypt Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. Reasons to Buy This Report 1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Herpes Labialis (Oral Herpes) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market. 2. This report will help stakeholders to understand the global industry status and trends of Drugs for Herpes Labialis (Oral Herpes) and provides them with information on key market drivers, restraints, challenges, and opportunities. 3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition. 4. This report stays updated with novel technology integration, features, and the latest developments in the market 5. This report helps stakeholders to gain insights into which regions to target globally 6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Herpes Labialis (Oral Herpes). 7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution. Chapter Outline Chapter 1: Research objectives, research methods, data sources, data cross-validation; Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 6: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc. Chapter 13: The main points and conclusions of the report.

目錄 Table of Contents

1 Preface 1.1 Scope of Report 1.2 Reasons for Doing This Study 1.3 Research Methodology 1.4 Research Process 1.5 Data Source 1.5.1 Secondary Sources 1.5.2 Primary Sources 2 Market Overview 2.1 Product Definition 2.2 Drugs for Herpes Labialis (Oral Herpes) by Type 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) 2.2.2 Aciclovir 2.2.3 Valacyclovir 2.2.4 Famciclovir 2.2.5 Docosanol 2.2.6 Other 2.3 Drugs for Herpes Labialis (Oral Herpes) by Application 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) 2.3.2 External Use 2.3.3 Oral 2.3.4 Injection 2.4 Assumptions and Limitations 3 Drugs for Herpes Labialis (Oral Herpes) Breakdown Data by Type 3.1 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Type (2021-2026) 3.2 Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Type (2027-2032) 4 Drugs for Herpes Labialis (Oral Herpes) Breakdown Data by Application 4.1 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Application (2021-2026) 4.2 Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Application (2027-2032) 5 Global Growth Trends 5.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Perspective (2021-2032) 5.2 Global Drugs for Herpes Labialis (Oral Herpes) Growth Trends by Region 5.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region: 2021 VS 2025 VS 2032 5.2.2 Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Region (2021-2026) 5.2.3 Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Region (2027-2032) 5.3 Drugs for Herpes Labialis (Oral Herpes) Market Dynamics 5.3.1 Drugs for Herpes Labialis (Oral Herpes) Industry Trends 5.3.2 Drugs for Herpes Labialis (Oral Herpes) Market Drivers 5.3.3 Drugs for Herpes Labialis (Oral Herpes) Market Challenges 5.3.4 Drugs for Herpes Labialis (Oral Herpes) Market Restraints 6 Market Competitive Landscape by Players 6.1 Global Top Drugs for Herpes Labialis (Oral Herpes) Players by Revenue 6.1.1 Global Top Drugs for Herpes Labialis (Oral Herpes) Players by Revenue (2021-2026) 6.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Players (2021-2026) 6.2 Global Drugs for Herpes Labialis (Oral Herpes) Industry Players Ranking, 2023 VS 2024 VS 2025 6.3 Global Key Players of Drugs for Herpes Labialis (Oral Herpes) Head Office and Area Served 6.4 Global Drugs for Herpes Labialis (Oral Herpes) Players, Product Type & Application 6.5 Global Drugs for Herpes Labialis (Oral Herpes) Manufacturers Established Date 6.6 Global Drugs for Herpes Labialis (Oral Herpes) Market CR5 and HHI 6.7 Global Players Mergers & Acquisition 7 North America 7.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032) 7.2 North America Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 7.3 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) 7.4 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) 7.5 United States 7.5 United States 7.6 Canada 7.7 Mexico 8 Europe 8.1 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032) 8.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 8.3 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) 8.4 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) 8.5 Germany 8.6 France 8.7 U.K. 8.8 Italy 8.9 Spain 8.10 Russia 8.11 Netherlands 8.12 Nordic Countries 9 Asia-Pacific 9.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032) 9.2 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 9.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) 9.4 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) 9.5 China 9.6 Japan 9.7 South Korea 9.8 India 9.9 Australia 9.10 China Taiwan 9.11 Southeast Asia 10 South America 10.1 South America Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032) 10.2 South America Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 10.3 South America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) 10.4 South America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) 10.5 Brazil 10.6 Argentina 10.7 Chile 10.8 Colombia 10.9 Peru 11 Middle East & Africa 11.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size (2021-2032) 11.2 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 11.3 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) 11.4 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) 11.5 Saudi Arabia 11.6 Israel 11.7 United Arab Emirates 11.8 Turkey 11.9 Iran 11.10 Egypt 12 Players Profiled 12.1 GSK 12.1.1 GSK Company Information 12.1.2 GSK Business Overview 12.1.3 GSK Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.1.4 GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.1.5 GSK Recent Developments 12.2 Novartis 12.2.1 Novartis Company Information 12.2.2 Novartis Business Overview 12.2.3 Novartis Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.2.4 Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.2.5 Novartis Recent Developments 12.3 Teva 12.3.1 Teva Company Information 12.3.2 Teva Business Overview 12.3.3 Teva Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.3.4 Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.3.5 Teva Recent Developments 12.4 Mylan 12.4.1 Mylan Company Information 12.4.2 Mylan Business Overview 12.4.3 Mylan Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.4.4 Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.4.5 Mylan Recent Developments 12.5 Cadila 12.5.1 Cadila Company Information 12.5.2 Cadila Business Overview 12.5.3 Cadila Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.5.4 Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.5.5 Cadila Recent Developments 12.6 Apotex 12.6.1 Apotex Company Information 12.6.2 Apotex Business Overview 12.6.3 Apotex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.6.4 Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.6.5 Apotex Recent Developments 12.7 Daewoong Pharmaceutical 12.7.1 Daewoong Pharmaceutical Company Information 12.7.2 Daewoong Pharmaceutical Business Overview 12.7.3 Daewoong Pharmaceutical Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.7.4 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.7.5 Daewoong Pharmaceutical Recent Developments 12.8 Livzon 12.8.1 Livzon Company Information 12.8.2 Livzon Business Overview 12.8.3 Livzon Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.8.4 Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.8.5 Livzon Recent Developments 12.9 Luoxin 12.9.1 Luoxin Company Information 12.9.2 Luoxin Business Overview 12.9.3 Luoxin Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.9.4 Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.9.5 Luoxin Recent Developments 12.10 Med shine 12.10.1 Med shine Company Information 12.10.2 Med shine Business Overview 12.10.3 Med shine Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.10.4 Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.10.5 Med shine Recent Developments 12.11 Bayer (Campho Phenique) 12.11.1 Bayer (Campho Phenique) Company Information 12.11.2 Bayer (Campho Phenique) Business Overview 12.11.3 Bayer (Campho Phenique) Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.11.4 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.11.5 Bayer (Campho Phenique) Recent Developments 12.12 Blistex 12.12.1 Blistex Company Information 12.12.2 Blistex Business Overview 12.12.3 Blistex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.12.4 Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.12.5 Blistex Recent Developments 12.13 Kelun 12.13.1 Kelun Company Information 12.13.2 Kelun Business Overview 12.13.3 Kelun Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.13.4 Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.13.5 Kelun Recent Developments 12.14 Hikma 12.14.1 Hikma Company Information 12.14.2 Hikma Business Overview 12.14.3 Hikma Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.14.4 Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.14.5 Hikma Recent Developments 12.15 Haiwang 12.15.1 Haiwang Company Information 12.15.2 Haiwang Business Overview 12.15.3 Haiwang Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.15.4 Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.15.5 Haiwang Recent Developments 12.16 Carmex 12.16.1 Carmex Company Information 12.16.2 Carmex Business Overview 12.16.3 Carmex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.16.4 Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.16.5 Carmex Recent Developments 12.17 Cipher 12.17.1 Cipher Company Information 12.17.2 Cipher Business Overview 12.17.3 Cipher Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) 12.17.4 Cipher Drugs for Herpes Labialis (Oral Herpes) Product Portfolio 12.17.5 Cipher Recent Developments 13 Report Conclusion 14 Disclaimer

圖表清單 List of Tables & Figures

List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Type (2021-2026) Table 7. Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Type (2027-2032) Table 9. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Application (2021-2026) Table 11. Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Application (2027-2032) Table 13. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region (2021-2026) Table 16. Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region (2027-2032) Table 18. Drugs for Herpes Labialis (Oral Herpes) Industry Trends Table 19. Drugs for Herpes Labialis (Oral Herpes) Industry Drivers Table 20. Drugs for Herpes Labialis (Oral Herpes) Industry Opportunities and Challenges Table 21. Drugs for Herpes Labialis (Oral Herpes) Market Restraints Table 22. Global Top Drugs for Herpes Labialis (Oral Herpes) Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Players (2021-2026) Table 24. Global Drugs for Herpes Labialis (Oral Herpes) Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Drugs for Herpes Labialis (Oral Herpes), Headquarters and Area Served Table 26. Global Drugs for Herpes Labialis (Oral Herpes) Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Drugs for Herpes Labialis (Oral Herpes) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2027-2032) & (US$ Million) Table 45. GSK Company Information Table 46. GSK Business Overview Table 47. GSK Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 48. GSK Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 49. GSK Recent Developments Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 53. Novartis Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 54. Novartis Recent Developments Table 55. Teva Company Information Table 56. Teva Business Overview Table 57. Teva Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 58. Teva Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 59. Teva Recent Developments Table 60. Mylan Company Information Table 61. Mylan Business Overview Table 62. Mylan Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 63. Mylan Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 64. Mylan Recent Developments Table 65. Cadila Company Information Table 66. Cadila Business Overview Table 67. Cadila Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 68. Cadila Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 69. Cadila Recent Developments Table 70. Apotex Company Information Table 71. Apotex Business Overview Table 72. Apotex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 73. Apotex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 74. Apotex Recent Developments Table 75. Daewoong Pharmaceutical Company Information Table 76. Daewoong Pharmaceutical Business Overview Table 77. Daewoong Pharmaceutical Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 78. Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 79. Daewoong Pharmaceutical Recent Developments Table 80. Livzon Company Information Table 81. Livzon Business Overview Table 82. Livzon Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 83. Livzon Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 84. Livzon Recent Developments Table 85. Luoxin Company Information Table 86. Luoxin Business Overview Table 87. Luoxin Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 88. Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 89. Luoxin Recent Developments Table 90. Med shine Company Information Table 91. Med shine Business Overview Table 92. Med shine Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 93. Med shine Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 94. Med shine Recent Developments Table 95. Bayer (Campho Phenique) Company Information Table 96. Bayer (Campho Phenique) Business Overview Table 97. Bayer (Campho Phenique) Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 98. Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 99. Bayer (Campho Phenique) Recent Developments Table 100. Blistex Company Information Table 101. Blistex Business Overview Table 102. Blistex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 103. Blistex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 104. Blistex Recent Developments Table 105. Kelun Company Information Table 106. Kelun Business Overview Table 107. Kelun Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 108. Kelun Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 109. Kelun Recent Developments Table 110. Hikma Company Information Table 111. Hikma Business Overview Table 112. Hikma Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 113. Hikma Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 114. Hikma Recent Developments Table 115. Haiwang Company Information Table 116. Haiwang Business Overview Table 117. Haiwang Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 118. Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 119. Haiwang Recent Developments Table 120. Carmex Company Information Table 121. Carmex Business Overview Table 122. Carmex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 123. Carmex Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 124. Carmex Recent Developments Table 125. Cipher Company Information Table 126. Cipher Business Overview Table 127. Cipher Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) & (US$ Million) Table 128. Cipher Drugs for Herpes Labialis (Oral Herpes) Product Portfolio Table 129. Cipher Recent Developments Table 130. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Drugs for Herpes Labialis (Oral Herpes) Product Image Figure 5. Global Drugs for Herpes Labialis (Oral Herpes) Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Type: 2025 VS 2032 Figure 7. Aciclovir Product Figure 8. Valacyclovir Product Figure 9. Famciclovir Product Figure 10. Docosanol Product Figure 11. Other Product Figure 12. Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Application: 2025 VS 2032 Figure 14. External Use Product Figure 15. Oral Product Figure 16. Injection Product Figure 17. Global Drugs for Herpes Labialis (Oral Herpes) Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 18. Global Drugs for Herpes Labialis (Oral Herpes) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Region: 2025 VS 2032 Figure 20. Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Players in 2025 Figure 21. Global Drugs for Herpes Labialis (Oral Herpes) Manufacturers Established Date Figure 22. Global Top 5 and 10 Drugs for Herpes Labialis (Oral Herpes) Players Market Share by Revenue in 2025 Figure 23. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. North America Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 26. United States Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Canada Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Mexico Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 29. Europe Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 31. Germany Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. France Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. U.K. Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Italy Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Spain Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Russia Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Netherlands Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Nordic Countries Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 41. China Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. Japan Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. South Korea Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. India Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. India Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 46. Australia Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. China Taiwan Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. South America Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. South America Drugs for Herpes Labialis (Oral Herpes) Market Share by Country (2021-2032) Figure 51. Brazil Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Argentina Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Chile Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Colombia Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Peru Drugs for Herpes Labialis (Oral Herpes) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 56. GSK Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 57. Novartis Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 58. Teva Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 59. Mylan Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 60. Cadila Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 61. Apotex Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 62. Daewoong Pharmaceutical Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 63. Livzon Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 64. Luoxin Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 65. Med shine Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 66. Bayer (Campho Phenique) Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 67. Blistex Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 68. Kelun Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 69. Hikma Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 70. Haiwang Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 71. Carmex Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026) Figure 72. Cipher Revenue Growth Rate in Drugs for Herpes Labialis (Oral Herpes) Business (2021-2026)

Single User	$2,950 USD
Multi User	$4,430 USD
Enterprise	$5,900 USD

Drugs for Herpes Labialis (Oral Herpes) Industry Research Report 2026

授權報價

報告摘要

提及公司